Form 8-K - Current report:
SEC Accession No. 0001193125-21-265999
Filing Date
2021-09-07
Accepted
2021-09-07 07:14:03
Documents
14
Period of Report
2021-09-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d194596d8k.htm   iXBRL 8-K 28832
2 EX-99.1 d194596dex991.htm EX-99.1 10647
6 GRAPHIC g194596g0903203536304.jpg GRAPHIC 2967
  Complete submission text file 0001193125-21-265999.txt   168080

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20210903.xsd EX-101.SCH 2881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20210903_lab.xml EX-101.LAB 17372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20210903_pre.xml EX-101.PRE 10945
7 EXTRACTED XBRL INSTANCE DOCUMENT d194596d8k_htm.xml XML 3233
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 211238247
SIC: 2836 Biological Products, (No Diagnostic Substances)